Clinical trials
Gastric / Gastroesophageal Junction Adenocarcinoma clinical trials
Below are recruiting gastric / gastroesophageal junction adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 175 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07544589RecruitingPhase 1
Testing DISP-10 for Advanced Gastrointestinal Cancers
This early-stage trial tests a new experimental therapy called DISP-10 in patients with advanced cancers of the stomach, esophagus, or colon that have spread. The goal is to see if this treatment can help shrink tumors and how safe it is.
Duarte, CaliforniaAges 18 years+ - NCT06902545Recruiting
Safety study of VYLOY for stomach or GEJ cancer in South Korea
This study monitors the safety of VYLOY (a cancer medicine) given to people in South Korea with stomach or gastroesophageal junction cancer. It helps doctors learn more about real-world side effects and how well patients do on treatment.
Goyang-si, Gyeonggi-doAges Any age - NCT07776639RecruitingPhase 2
Immunotherapy with chemotherapy before surgery for stomach cancer
This trial tests whether adding an immunotherapy drug (QL1706) to a standard chemotherapy regimen, given before surgery, can help shrink stomach or gastroesophageal junction cancer. The goal is to improve the chance of successful surgery and long-term outcomes.
Zhengzhou, HenanAges 18–75 - NCT05269381RecruitingPhase 1/Phase 2
Personalized cancer vaccine with pembrolizumab for advanced solid tumors
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
Jacksonville, FloridaAges 16 years+ - NCT05205343Recruiting
Compare minimally invasive and full stomach surgery for upper cancer
This study compares two minimally invasive ways to operate on the stomach area for cancers near the stomach and esophagus (GEJ). It looks at whether one surgical approach is better for long-term outcomes when the goal is cure.
Rochester, MinnesotaAges 18 years+ - NCT07546812RecruitingPhase 2
Testing Denikitug for advanced stomach and esophageal cancer
This study tests a new drug called denikitug, alone or combined with other cancer treatments, for patients with advanced stomach, gastroesophageal junction, or esophageal adenocarcinoma that has progressed after initial treatment. The drug targets immune cells to help your body fight cancer.
Boston, MassachusettsAges 18 years+ - NCT07001748RecruitingPhase 2/Phase 3
Testing abdominal chemo plus standard chemo for stomach cancer spread
This trial tests adding the chemotherapy drug paclitaxel directly into the abdomen (intraperitoneal) along with standard IV chemotherapy for people with stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen. The goal is to see if this combination helps control the cancer better than standard treatment alone.
Irvine, CaliforniaAges 18 years+ - NCT06826079RecruitingPhase 2
Sorbitol plus chemo and immunotherapy for advanced gastric cancer
This trial tests adding sorbitol to standard chemotherapy and an immunotherapy drug (tirellizumab) for people with locally advanced stomach cancer. The goal is to see if this combination is safe and helps shrink tumors before surgery.
Wuhan, HubeiAges 18–70 - NCT06846996Recruiting
Study of trastuzumab deruxtecan for advanced stomach cancer
This study looks at how well the drug trastuzumab deruxtecan (T-DXd) works and how safe it is in people with advanced HER2-positive stomach or gastroesophageal junction cancer in China. It may be an option if you have already had other treatments.
BeijingAges 18 years+ - NCT07552402Recruiting
Oral Paclitaxel Plus Fruquintinib for Advanced Stomach Cancer
This trial tests a combination of two oral drugs (paclitaxel and fruquintinib) for advanced stomach cancer that has already been treated with one round of chemotherapy. The goal is to see if this combination helps control the cancer better than other standard second-line treatments.
Shijiazhuang, HebeiAges 18–75 - NCT07392892RecruitingPhase 2/Phase 3
Study of PF-08634404 plus chemo for stomach and esophagus cancer
This trial tests a new study drug called PF-08634404 in combination with standard chemotherapy for people with stomach, gastroesophageal junction, or esophagus cancer that has spread. It aims to see if adding this drug helps the treatment work better.
Aurora, ColoradoAges 18 years+ - NCT04221893Recruiting
Radiation therapy for metastatic gastrointestinal cancers
This trial tests whether adding radiation therapy to your current immunotherapy can help control cancer that has spread in the digestive system. It aims to improve symptoms and possibly slow the cancer's growth.
San Francisco, CaliforniaAges 18 years+ - NCT07751302Recruiting
Follow-up vs. chemo after surgery for early stomach cancer
This trial compares two approaches after surgery for early-stage stomach or GEJ cancer: close monitoring (follow-up) vs. adjuvant chemotherapy (chemo given after surgery). It aims to see if follow-up alone is as good as chemo for patients with this stage, potentially avoiding chemo side effects.
Xi'an, ShaanxiAges 18 years+ - NCT04615013RecruitingPhase 1
NBTXR3 with chemoradiation for esophageal cancer treatment
This early-phase study tests adding NBTXR3 (a special treatment given into the tumor) to standard chemotherapy and radiation for esophageal cancer. The goal is to see if it can improve cancer control and to learn about safety and dosing.
Houston, TexasAges 18 years+ - NCT06324357RecruitingPhase 1/Phase 2
Zongertinib for HER2-positive cancers that have spread
This trial tests a new pill called zongertinib, alone or with other drugs, for people with HER2-positive cancers (like breast, stomach, or colorectal cancer) that have spread and are no longer responding to standard treatments. The goal is to find the best dose and see if it can help shrink tumors or slow the disease.
Cerritos, CaliforniaAges 18 years+ - NCT06642857Recruiting
Predicting treatment response for advanced stomach cancer
This trial uses advanced testing to predict how well stomach cancer responds to chemotherapy combined with immunotherapy. It may help find the best treatment for advanced or metastatic stomach or gastroesophageal junction cancer that hasn't been treated yet.
Hangzhou, ZhejiangAges 18–75 - NCT06649292RecruitingPhase 3
Study of SHR-A1904 for gastric cancer with CLDN18.2
This trial tests a new drug called SHR-A1904 against standard treatments for people with advanced stomach or gastroesophageal junction cancer that has already been treated once. It is for those whose tumors are positive for a protein called CLDN18.2.
Guangzhou, GuangdongAges 18–75 - NCT06572319RecruitingPhase 1/Phase 2
Combination drug trial for HER2-positive stomach cancer
This trial tests two drugs, disitamab vedotin and trastuzumab, for people with HER2-positive stomach or gastroesophageal junction cancer that has spread or come back after at least one prior treatment. The goal is to see if this combination can help shrink tumors.
Hangzhou, ZhejiangAges 18–75 - NCT06163729RecruitingPhase 2
Testing camrelizumab plus chemo and radiation before/after surgery for stomach-esophagus cancer
This trial tests combining the immunotherapy drug camrelizumab with chemotherapy and radiation before and after surgery for a specific type of stomach-esophagus cancer. It aims to see if this approach helps shrink the tumor and improve outcomes.
Beijing, Beijing MunicipalityAges 18–80 - NCT07118527RecruitingPhase 3
New drug combo for untreated advanced stomach cancer
This trial tests a new combination of an anti-HER2 drug (SHR-A1811) plus chemotherapy and an immunotherapy (adebrelimab) for people with untreated advanced stomach cancer. It aims to see if this combination works better than standard treatment.
Shenyang, LiaoningAges 18–75 - NCT06341335RecruitingPhase 3
AK104 and AK109 plus paclitaxel for advanced stomach cancer
This trial tests a combination of two experimental immunotherapies (AK104 and AK109) with a standard chemo drug (paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has grown after initial treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer better than chemo alone.
BeijingAges 18–75 - NCT06841679RecruitingPhase 2/Phase 3
Testing utidelone plus chemo for untreated stomach cancer
This trial tests a new capsule (utidelone) combined with standard chemotherapy as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. It aims to see if this combination works better than current options.
Hialeah, FloridaAges 18 years+ - NCT06406426RecruitingPhase 2
New drug combo for advanced stomach cancer after first treatment fails
This trial tests a combination of three drugs—cadonilimab, fruquintinib, and albumin-bound paclitaxel—as a second treatment for advanced stomach cancer. It may be an option if your first treatment stopped working and you have not had certain types of prior therapy.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06764875RecruitingPhase 3
New drug combo for HER2-positive stomach cancer
This trial tests a new immunotherapy called rilvegostomig combined with standard chemotherapy and a targeted therapy (trastuzumab deruxtecan) for people with advanced HER2-positive stomach or gastroesophageal junction cancer that has not been treated before.
Anchorage, AlaskaAges 18 years+
Hear when a new Gastric / Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Gastric / Gastroesophageal Junction Adenocarcinoma trials by city
Studies with a site in or near these metro areas.
Gastric / Gastroesophageal Junction Adenocarcinoma trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for gastric / gastroesophageal junction adenocarcinoma?
- Yes. Clin2 currently lists 175 recruiting gastric / gastroesophageal junction adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a gastric / gastroesophageal junction adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a gastric / gastroesophageal junction adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Gastric or Gastroesophageal Junction Adenocarcinoma
- AFP Gastric or Gastroesophageal Junction Adenocarcinoma
- Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
- Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- Metastatic Gastroesophageal Junction Adenocarcinoma
- Gastroesophageal Junction (GEJ) Adenocarcinoma
- Advanced Gastroesophageal Junction Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.